These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 28802907)
21. Intensive chemotherapy and reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in elderly patients. Jackson K; Kennedy G; Mollee P; Marlton P; Morris K Asia Pac J Clin Oncol; 2014 Sep; 10(3):246-54. PubMed ID: 24673966 [TBL] [Abstract][Full Text] [Related]
22. Wilms Tumor 1 Expression and Pre-emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation. Di Grazia C; Pozzi S; Geroldi S; Grasso R; Miglino M; Colombo N; Tedone E; Luchetti S; Lamparelli T; Gualandi F; Ibatici A; Bregante S; Van Lint MT; Raiola AM; Dominietto A; Varaldo R; Galaverna F; Ghiso A; Sica S; Bacigalupo A Biol Blood Marrow Transplant; 2016 Jul; 22(7):1242-1246. PubMed ID: 26970379 [TBL] [Abstract][Full Text] [Related]
23. Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Malard F; Labopin M; Stuhler G; Bittenbring J; Ganser A; Tischer J; Michallet M; Kröger N; Schmid C; Huynh A; Hallek M; Savani BN; Mohty M; Nagler A Biol Blood Marrow Transplant; 2017 Feb; 23(2):278-284. PubMed ID: 27816650 [TBL] [Abstract][Full Text] [Related]
24. Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. Oran B; Jimenez AM; De Lima M; Popat UR; Bassett R; Andersson B; Borthakur G; Bashir Q; Chen J; Ciurea SO; Jabbour E; Cortes J; Kebriaei P; Khouri IF; Qazilbash MH; Ravandi F; Rondon G; Lu X; Shpall EJ; Champlin RE Biol Blood Marrow Transplant; 2015 Aug; 21(8):1405-1412. PubMed ID: 25840338 [TBL] [Abstract][Full Text] [Related]
25. Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study. Nasilowska-Adamska B; Czyz A; Markiewicz M; Rzepecki P; Piatkowska-Jakubas B; Paluszewska M; Dzierzak-Mietla M; Solarska I; Borg K; Prochorec-Sobieszek M; Szydlo R; Lewandowski K; Skotnicki A; Jedrzejczak WW; Kyrcz-Krzemien S; Komarnicki M; Warzocha K Eur J Haematol; 2016 Mar; 96(3):236-44. PubMed ID: 25912052 [TBL] [Abstract][Full Text] [Related]
26. Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemia. Aoki J; Kanamori H; Tanaka M; Yamasaki S; Fukuda T; Ogawa H; Iwato K; Ohashi K; Okumura H; Onizuka M; Maesako Y; Teshima T; Kobayashi N; Morishima Y; Hirokawa M; Atsuta Y; Yano S; Takami A Am J Hematol; 2016 Mar; 91(3):302-7. PubMed ID: 26663096 [TBL] [Abstract][Full Text] [Related]
27. Impact of allogeneic hematopoietic cell transplantation on the outcome of older patients with acute myeloid leukemia. Appelbaum FR Best Pract Res Clin Haematol; 2017 Dec; 30(4):320-326. PubMed ID: 29156203 [TBL] [Abstract][Full Text] [Related]
28. Role of reduced-intensity conditioning allogeneic hematopoietic cell transplantation in older patients with de novo acute myeloid leukemia. Yamasaki S; Hirakawa A; Aoki J; Uchida N; Fukuda T; Ogawa H; Ohashi K; Kondo T; Eto T; Kanamori H; Okumura H; Iwato K; Ichinohe T; Kanda J; Onizuka M; Kuwatsuka Y; Yanada M; Atsuta Y; Takami A; Yano S Ann Hematol; 2017 Feb; 96(2):289-297. PubMed ID: 27838773 [TBL] [Abstract][Full Text] [Related]
32. Central Nervous System Involvement at the Time of Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with a Poor Outcome in Patients with Acute Myeloid Leukemia. Ikegawa S; Doki N; Kaito S; Kurosawa S; Sakaguchi M; Harada K; Yamamoto K; Hino Y; Shingai N; Senoo Y; Watanabe D; Hagino T; Yoshioka K; Watakabe K; Igarashi A; Najima Y; Kobayashi T; Kakihana K; Sakamaki H; Ohashi K Pathol Oncol Res; 2017 Apr; 23(2):433-437. PubMed ID: 28004352 [TBL] [Abstract][Full Text] [Related]
33. Harnessing the immune system after allogeneic stem cell transplant in acute myeloid leukemia. Sterling C; Webster J Am J Hematol; 2020 May; 95(5):529-547. PubMed ID: 32022292 [TBL] [Abstract][Full Text] [Related]
34. Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis. Michelis FV; Gupta V; Zhang MJ; Wang HL; Aljurf M; Bacher U; Beitinjaneh A; Chen YB; DeFilipp Z; Gale RP; Kebriaei P; Kharfan-Dabaja M; Lazarus HM; Nishihori T; Olsson RF; Oran B; Rashidi A; Rizzieri DA; Tallman MS; de Lima M; Khoury HJ; Sandmaier BM; Weisdorf D; Saber W; Cancer; 2017 Jun; 123(11):2035-2042. PubMed ID: 28117898 [TBL] [Abstract][Full Text] [Related]
35. Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial. Pfirrmann M; Ehninger G; Thiede C; Bornhäuser M; Kramer M; Röllig C; Hasford J; Schaich M; Lancet Oncol; 2012 Feb; 13(2):207-14. PubMed ID: 22197676 [TBL] [Abstract][Full Text] [Related]
36. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies. Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713 [TBL] [Abstract][Full Text] [Related]
37. Assessing the efficacy of allogeneic hematopoietic stem cells transplantation (allo-HSCT) by analyzing survival end points in defined groups of acute myeloid leukemia patients: a retrospective, multicenter Polish Adult Leukemia Group study. Grosicki S; Holowiecki J; Kuliczkowski K; Skotnicki A; Hellmann A; Kyrcz-Krzemien S; Dmoszynska A; Sułek K; Kloczko J; Jedrzejczak WW; Warzocha K; Zdziarska B; Wierzbowska A; Pluta A; Komarnicki M; Giebel S Am J Hematol; 2015 Oct; 90(10):904-9. PubMed ID: 26149802 [TBL] [Abstract][Full Text] [Related]
39. Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD-Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-Transplantation. Schiller GJ; Tuttle P; Desai P Biol Blood Marrow Transplant; 2016 Jun; 22(6):982-990. PubMed ID: 26785334 [TBL] [Abstract][Full Text] [Related]
40. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia. Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]